188 related articles for article (PubMed ID: 36780008)
1. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
Pan E; Xie W; Ajmera A; Araneta A; Jamieson C; Folefac E; Hussain A; Kyriakopoulos CE; Olson A; Parikh M; Parikh R; Saraiya B; Ivy SP; Van Allen EM; Lindeman NI; Kochupurakkal BS; Shapiro GI; McKay RR
Mol Cancer Ther; 2023 Apr; 22(4):511-518. PubMed ID: 36780008
[TBL] [Abstract][Full Text] [Related]
2. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP
J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
6. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS
Eur Urol; 2023 Jan; 83(1):15-26. PubMed ID: 36055895
[TBL] [Abstract][Full Text] [Related]
8. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Fong L; Morris MJ; Sartor O; Higano CS; Pagliaro L; Alva A; Appleman LJ; Tan W; Vaishampayan U; Porcu R; Tayama D; Kadel EE; Yuen KC; Datye A; Armstrong AJ; Petrylak DP
Clin Cancer Res; 2021 Sep; 27(17):4746-4756. PubMed ID: 34108181
[TBL] [Abstract][Full Text] [Related]
10. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F; VanderWeele D; Madan RA; Owens H; Cordes LM; Hankin A; Couvillon A; Nichols E; Bilusic M; Beshiri ML; Kelly K; Krishnasamy V; Lee S; Lee MJ; Yuno A; Trepel JB; Merino MJ; Dittamore R; Marté J; Donahue RN; Schlom J; Killian KJ; Meltzer PS; Steinberg SM; Gulley JL; Lee JM; Dahut WL
J Immunother Cancer; 2018 Dec; 6(1):141. PubMed ID: 30514390
[TBL] [Abstract][Full Text] [Related]
11. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
Quinn Z; Leiby B; Sonpavde G; Choudhury AD; Sweeney C; Einstein D; Szmulewitz R; Sartor O; Knudsen K; Yang ES; Kelly WK
Clin Cancer Res; 2023 Jan; 29(1):50-59. PubMed ID: 36321991
[TBL] [Abstract][Full Text] [Related]
13. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Matsubara N; Nishimura K; Kawakami S; Joung JY; Uemura H; Goto T; Kwon TG; Sugimoto M; Kato M; Wang SS; Pang ST; Chen CH; Fujita T; Nii M; Shen L; Dujka M; Hussain M; de Bono J
Jpn J Clin Oncol; 2022 May; 52(5):441-448. PubMed ID: 35229141
[TBL] [Abstract][Full Text] [Related]
14. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
15. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
[TBL] [Abstract][Full Text] [Related]
16. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
17. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
18. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
19. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
de Kouchkovsky I; Rao A; Carneiro BA; Zhang L; Lewis C; Phone A; Small EJ; Friedlander T; Fong L; Paris PL; Ryan CJ; Szmulewitz RZ; Aggarwal R
Clin Cancer Res; 2022 Apr; 28(8):1531-1539. PubMed ID: 35176163
[TBL] [Abstract][Full Text] [Related]
20. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
